Glycans mediate virtually all biological processes, such as cell-pathogen interaction, disease progression, and immune response modulation. Finding these mediator glycans and targeting them for therapeutic purposes has been very challenging due to the exquisitely complex nature of the biological system. Our focus is on finding these mediator glycans, through high throughput Glycomics, that we can use as glycan-based biomarker and as a therapeutic target.
Our goal is to design and develop therapeutic glycan mimics based on disease-specific glycan markers and take advantage of these markers as molecular targets in the delivery of therapeutic agents, using Nanoparticle-based Drug Delivery System (NDDS), with minimal perturbation and on the biological system. We have established a delivery platform that evades endolysosomal sequestration during intracellular delivery and successfully allowed glycan-guided organelle targeting (ACS Chem. Biol., 2015, 10 (9), pp 2073–2086). Coupled with this platform, we aim to fine-tune this technique and design a unique and comprehensive delivery system using a ‘bottom-up’ approach.
Our goal is to design and develop therapeutic glycan mimics based on disease-specific glycan markers and take advantage of these markers as molecular targets in the delivery of therapeutic agents, using Nanoparticle-based Drug Delivery System (NDDS), with minimal perturbation and on the biological system. We have established a delivery platform that evades endolysosomal sequestration during intracellular delivery and successfully allowed glycan-guided organelle targeting (ACS Chem. Biol., 2015, 10 (9), pp 2073–2086). Coupled with this platform, we aim to fine-tune this technique and design a unique and comprehensive delivery system using a ‘bottom-up’ approach.